Objective: To investigate whether the addition of liposomal bupivacaine abdominal wall blocks to a multimodal analgesic regimen improves postoperative numeric rating scale pain scores and reduces opioid consumption in patients undergoing living liver donation. Patients and Methods: We conducted a single-center, retrospective review of patients who underwent living liver donation from January 1, 2011, through February 19, 2016, and received multimodal analgesia with (block group) or without (control group) abdominal wall blockade. The block solution consisted of liposomal bupivacaine (266 mg) mixed with 30 mL of 0.25% bupivacaine. Both groups received intrathecal hydromorphone. Main outcome measures were pain scores, opioid requirements, time to full diet, and bowel activity. Results: Postoperative day 0 pain scores were significantly better in the block group (n¼29) than in the control group (n¼48) (2.4 vs 3.5; P¼.002) but were not significantly different on subsequent days. Opioid requirements were significantly decreased for the block group in the postanesthesia care unit (0 vs 9 mg oral morphine equivalents; P¼.002) and on postoperative day 0 (7 vs 18 mg oral morphine equivalents; P¼.004). Median (interquartile range) time to full diet was 23 hours (14-30 hours) in the block group and 38 hours (24-53 hours) in the control group (P¼.001); time to bowel activity was also shorter in the block group ( 
T he critical shortage of deceased donor liver allografts and the increased morbidity and mortality that patients experience while awaiting transplant have led to the use of living donor liver transplant. 1, 2 Because donor hepatectomy involves major upper abdominal surgery in healthy donors, analgesia is important for mitigating postoperative morbidity and is a primary concern for patients considering living donation. 3 Although epidural analgesia has historically been the standard of postoperative pain control, recent studies have found that postoperative coagulopathy may put patients at risk for neuraxial hematoma. 1, 4 Accordingly, alternative analgesic methods that avoid this risk have been used in the search for safe but effective pain management. 4, 5 Abdominal wall blockade involves depositing local anesthetic into the fascial plane superficial to the transversus abdominis muscle to anesthetize the distal branches of the anterior rami of the lower thoracic and upper lumbar nerve roots. 6 Although single-injection transversus abdominis plane (TAP) blocks can provide excellent analgesia for major abdominal surgery, their primary shortcomings include limitations in dermatomal spread and short duration, with comprehensive analgesia rarely extending beyond 12 hours. 6, 7 To extend analgesia duration, some investigators have placed TAP catheters to facilitate infusion of local anesthetic. 4, 5 To date, however, this technique has been limited by high failure rates of secondary analgesia. 8 The novel, long-acting, encapsulated local anesthetic liposomal bupivacaine has been reported to produce detectable serum bupivacaine concentrations for up to 96 hours. 9 Therefore, liposomal bupivacaine may extend the analgesia of abdominal wall blockade and improve postoperative pain control for living liver donation patients. Recently, Mayo Clinic added a multi-injection abdominal wall technique (specifically, lateral TAP and multiinjection subcostal TAP) with a liposomal bupivacaine mixture to our practice. This regional approach targets broader dermatomal innervation of the abdominal wall and may improve both coverage and duration of blockade.
We hypothesized that abdominal wall blockade for living liver donation patients would improve postoperative pain scores and reduce opioid consumption.
PATIENTS AND METHODS
After receiving Mayo Clinic Institutional Review Board approval, we searched the institutional liver transplant database to identify all patients undergoing living liver donation at Mayo Clinic, Rochester, Minnesota, from January 1, 2011, through February 19, 2016 . Living donor hepatectomy patients aged 18 to 60 years were included. Exclusion criteria were chronic pain syndromes (fibromyalgia, complex regional pain syndromes) and chronic opioid use (daily opioid consumption of >15 mg/d oral morphine equivalents [OME] for more than 1 month before liver donation).
American Society of Anesthesiologists (ASA) status, body mass index (calculated as the weight in kilograms divided by the height in meters squared), sex, and age were recorded for all patients. Patients were then screened for eligibility into 2 groups based on anesthetic intervention: use of abdominal wall blocks (block group) or no use of abdominal wall blocks (control group). The primary outcome measure was postoperative numeric rating scale (NRS) pain scores (0 ¼ no pain to 10 ¼ worst pain) on postoperative days (PODs) 0 and 1. Secondary outcomes included NRS pain scores in the postanesthesia care unit (PACU) and on PODs 2, 3, and 4; opioid consumption in the PACU and on PODs 0, 1, 2, 3, and 4; treatment for nausea and vomiting on PODs 0, 1, 2, 3, and 4; time to ingestion of clear fluids and a full diet; time to bowel activity; and hospital length of stay. Data were extracted from the electronic medical record using institutional perioperative database software by electronic query and via manual retrieval from the electronic medical and anesthesia records.
Multimodal Analgesia and Perioperative Protocol Mayo Clinic's multimodal analgesic clinical pathway for living liver donation consists of preoperative oral medications, perioperative systemic opioids and nonopioid medicines, and a preoperative intrathecal opioid. On arrival at the preoperative area, the patient is administered 800 mg of oral gabapentin. The patient is then transferred to the operating room suite, where a hydromorphone (100-150 mg) spinal is aseptically administered using primarily a 25-gauge Whitacre needle. General anesthesia is maintained with volatile anesthesia, intravenous (IV) opioids (fentanyl, <500 mg), nonopioid adjuvants (ketorolac, 15 mg IV, þ/À ketamine, 10 mg IV), and aggressive antiemetic prophylaxis (granisetron, 0.1 mg IV, or ondansetron, 4 mg IV, þ/À scopolamine transdermal patch, 1.5 mg, applied for 24-72 hours þ/À droperidol, 0.625 mg IV).
The regional anesthesia technique, when performed, was after wound closure. All the patients were extubated and transported to the PACU, where they were assessed for postoperative pain control and anesthetic recovery. On PACU departure they are transferred to the intensive care unit and monitored for 24 hours.
Surgical Technique
The surgical incision for living liver donation involves a primary right subcostal incision with a midline extension to the xiphoid. All the patients underwent a right or left hepatectomy with incidental cholecystectomy. 
Abdominal Wall Injection Technique

Statistical Analyses
Data are reported using median (interquartile range [IQR]) for continuous variables and frequency (percentage) for categorical variables. Daily pain scores were averaged for each patient across all available NRS pain scores in each period and are reported as the median (IQR) average pain score for the groups. Opioid use was converted to OME using standard institutional tables and is reported as median (IQR). Timing of diet, elimination, and hospital length of stay are similarly reported as median (IQR). Data were compared between groups using a rank sum test for continuous variables and a 2-tailed Fisher exact test for categorical variables. Two-sided tests were performed, with P<.05 denoting statistical significance. Data analyses were performed using both JMP Pro version 10.0.0 (SAS Institute Inc) and Stata version 9.3 (StataCorp LLC).
RESULTS
During the study period, 97 persons were living liver donors and met the inclusion criteria ( Figure 2 ). Of those patients, 1 was excluded because the TAP block was placed preoperatively, 4 were excluded because they did not receive an intrathecal opioid, and 15 were excluded because of surgeon-administered abdominal wound infiltration with local anesthetic under direct visualization. A total of 77 patients were analyzed, with 29 in the block group and 48 in the control group. The median age of participants was within 2 years, and body mass index was within 1 kg/m 2 between the groups ( Table 1 ). The block group had a slightly higher percentage of ASA I patients (79% vs 69% in the control group); given the rigorous (Table 2) . Furthermore, median (IQR) opioid requirements in the PACU were significantly lower for the block group vs the control group (0 mg OME [0-10 mg OME] vs 9 mg OME [1-25 mg OME]; P¼.002) and also on POD 0 (7 mg OME [0-15 mg OME] vs 18 mg OME [5-36 mg OME]; P¼.004), but no difference was seen on subsequent days (Table 3) . Two patients in the control group returned to the operating room within 30 days, one for retrieval of a broken abdominal drain on POD 9 and one for evacuation of a hematoma and to achieve hemostasis on POD 1. Two patients were readmitted within 30 days (one for a bile leak and one for a surgical site infection), both from the control group. Two patients required endoscopy with stent placement for bile leak, one from each group. No complications associated with abdominal wall blockade or intrathecal injection were noted.
DISCUSSION
This study reports improved initial postoperative analgesia using multi-injection liposomal bupivacaine abdominal wall blocks in conjunction with the established multimodal analgesic regimen for living liver donation. Furthermore, the addition of abdominal wall blocks in this group showed improved time to solid food intake and bowel activity, both indicators of enhanced recovery and improved patient satisfaction and outcomes. 10 Providing optimal and safe postoperative pain control for living hepatic donors is desirable for several reasons. 11 First, according to the American Transplant Foundation, 12 postoperative pain is a primary concern in persons considering liver donation. Second, the current demand for liver transplants is much greater than the available organ supply; thus, provision of safe and comfortable perioperative experiences influences living donor availability. 13 Finally, postoperative pain has been found to be a major cause of perioperative morbidity and mortality and is, thus, of special consideration in otherwise healthy donor patients. 14 With that in mind, every pain management technique for major abdominal surgery has its own set of risks and benefits. Although epidural placement provides excellent pain control for living liver donation, several studies have reported that postoperative coagulopathy places patients at risk for epidural hematoma. One study found that prothrombin times increased by 50% on POD 1, and another study found that one-third of patients had an international normalized ratio of 1.5 or higher over the same postoperative period during which epidural analgesia is typically required. 1, 15 Despite recent literature contradicting this concern by reporting a prothrombic state via thromboelastometry after major hepatic resection, many anesthesia providers are still reluctant to place an epidural catheter. 16 Individual abdominal wall blocks (lateral TAP, subcostal TAP, or rectus sheath blocks) have each been associated with improved pain control in isolation; however, their limited duration, visceral pain sparing, and inconsistent dermatomal coverage has led to inferior analgesia compared with an epidural technique. 17 For example, a lateral TAP block consistently provides coverage to the T10-T12 dermatomes but inconsistently anesthetizes the T9 and L1 dermatomal regions. 6 Støving et al 17 performed sensory mapping after a lateral TAP block in healthy volunteers and found a highly variable pattern of dermatomal blockade. Furthermore, single-injection subcostal TAP blocks have been found to consistently block T7-T9 dermatomes and inconsistently block T6 and T10. 4 Rozen et al 18 also reported that a rectus sheath block, performed at the lateral edge, missed 11% of the terminal anterior cutaneous branches. On the basis of these investigations, Although the pharmaceutical manufacturer's published data regarding liposomal bupivacaine indicates detectable serum levels 96 hours after administration, 9 head-to-head trials examining the duration of analgesia in liposomal and free bupivacaine have had conflicting results. 20, 21 The limited analgesic clinical benefit observed in the present study, although still potentially longer than published results for abdominal wall blockade with plain bupivacaine, remains considerably shorter than advertised data. However, it is possible that a dilution effect, in combining 75 mg of plain bupivacaine (added to improve onset time of block) with 266 mg of liposomal bupivacaine, also contributed to the shorter clinical effect of the regional technique. Furthermore, there has been hesitation among some organizations to adapt the routine use of liposomal bupivacaine for postoperative pain control given the added cost of this product over plain bupivacaine without concrete data showing a clear advantage.
This retrospective study has several strengths. The surgical procedure was performed at a large academic liver transplant center with consistent and uniform surgical techniques among surgeons. Furthermore, the surgical and anesthesia teams have worked collaboratively during the past 20 years to standardize the analgesic pathway for liver donation patients. This is also an ideal study population because of the homogeneity of good health among patients secondary to rigorous donor screening and selection criteria. Abdominal wall blockade is also easy to learn and perform using ultrasound guidance. Compared with catheter placement, it allows for less medical intervention, avoids dislodgement, and decreases the workload of placement and catheter management. The abdominal wall blocks also do not significantly extend the total length of the surgical procedure (Table 1) because they are placed after the incision is closed in the operating room and during patient emergence from anesthesia. Although only a few centers perform living liver donation, the application of this block technique could be easily transferred and applied to other major abdominal surgeries.
The main limitation of this study is the nonrandomized retrospective design, which lacks blinding to patients and providers. Statistically significant outcomes could also have been the result of a bias associated with implementation of a new technique into a surgical practice or changes in downstream care. The small sample size also means insufficient power to interpret data where no significant differences were detected (ie, hospital length of stay); therefore, the data presented are hypothesis generating and should be replicated with a large randomized controlled trial. Furthermore, near the end of the study period, the surgical incision technique changed slightly for 5 patients, who received a laparoscopic-assisted hepatectomy. These patients had an approximately 12-cm midline incision, a supraumbilical 10-mm trocar, and two 5-mm trocars in the right side of the abdomen. Despite the change, subset analysis excluding these 5 patients still found a significant difference in median (IQR) pain scores on POD 0 (block group: 2.5 [1-3.6]; control group: 3.5 [2.4-4.9]; P¼.009) and in median (IQR) total OME consumption in the PACU (block group: 0 mg OME [0-14 mg OME]; control group: 8 mg OME [1-25 mg OME]; P¼.009) and on POD 0 (block group: 7 mg OME [0-15 mg OME]; control group: 18 mg OME [5-36 mg OME]; P¼.01).
CONCLUSION
In summary, the addition of a multi-injection abdominal wall blockade to a comprehensive multimodal clinical pathway for living liver donation improves postoperative pain control and decreases time to full diet and bowel activity. Prospective, blinded, randomized clinical trials evaluating abdominal wall blockade with liposomal bupivacaine compared with free bupivacaine are needed to determine the utility of encapsulated bupivacaine with abdominal wall blocks.
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